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ABSTRACT
Objective: To predict the effect of nesiritide on clinical outcomes based
on the renal function change demonstrated in the Nesiritide Admini-
stered Peri-Anesthesia (NAPA) in patients undergoing cardiac surgery
trial.
Methods: We built a decision analytical model to replicate the NAPA trial
with 1000 hypothetical patients in both nesiritide and placebo arms. The
incident rates of dialysis, hospital death, and their composite were pre-
dicted based on the renal function data obtained from the NAPA trial. All
analyses were further repeated for two subgroups stratiﬁed by the presence
of preoperative renal dysfunction (RD).
Results: The base-case analyses signiﬁcantly favored nesiritide for the
three clinical end points. In the total NAPA sample, the absolute risk
reductions (ARRs) for dialysis, hospital death, and their composite across
100 simulated trials were 1.3%, 3.3%, and 4.1%, respectively. The
improvement was more pronounced in the preoperative RD subgroup
with the three ARRs of 4.1%, 7.1%, and 9.4%, respectively. The beneﬁ-
cial effect diminished in the normal preoperative renal function (NRF)
subgroup with the three ARRs of 0.6%, 3.0%, and 3.4%, respectively.
The best case analyses conﬁrmed the robustness of the base-case results in
the total NAPA sample and RD subgroup, but not in the NRF subgroup.
Conclusion: If the demonstrated renal preservation can be extrapolated,
nesiritide may reduce dialysis and hospital death in cardiac surgery patient
with preoperative RD, but to a much lesser extent or not in patients with
normal preoperative renal function.
Keywords: acute renal failure, cardiac surgery, decision tree analysis,
dialysis, hospital mortality, nesiritide.
Background
Acute renal failure (ARF) is one of the major postoperative
complications affecting up to 30% of the patients undergoing
cardiac surgery [1]. It is a strong predictor of serious morbidity,
excessive health-care resource utilization, and elevated mortality
in both short and long-term observations [1–7]. The hospital
mortality rate in patients requiring postoperative dialysis is more
than 50% [2,3]. Mild ARF not requiring dialysis, characterized
by a postoperative renal function decline, is also independently
associated with higher mortality rates [4–6]. Renal hypoperfu-
sion and ischemia are generally believed to be the causes of ARF.
Several prophylactic interventions have been investigated for this
life-threatening event.
Nesiritide (Natrecor, Scios Inc., Fremont, CA) is a human
B-type natriuretic peptide that was approved for the treatment of
decompensated congestive heart failure. It has multiple effects
including vasodilation, anti-aldosterone axis, and prodiuretic
effects. Nesiritide is thought to prevent ARF in cardiac surgery
patients by maintaining glomerular ﬁltration through relative
afferent renal arteriole dilation [8,9]. A randomized double-
blinded, placebo-controlled clinical trial, the Nesiritide Adminis-
tered Peri-Anesthesia (NAPA) trial in patients undergoing cardiac
surgery demonstrated a renal beneﬁt of nesiritide in patients with
left ventricular dysfunction undergoing coronary artery bypass
graft surgery [10]. Nesiritide was given intravenously at a ﬁxed
low dose of 0.01 mg/kg/min without bolus, after induction of
anesthesia but before chest incision for 24–96 hours. Compared
with the placebo arm, the nesiritide arm had improved renal
function during the postoperative period, indicated by less
maximum decline in glomerular ﬁltration rate (GFR) and less
maximum increase in serum creatinine (SCr). The improvement
was more prominent in patients with preoperative renal dysfunc-
tion (RD). The other favoring ﬁndings included signiﬁcantly
greater urine output and less total hospital length of stay.
However, the efﬁcacy estimates on “hard” clinical end points were
inconclusive. The incidence rates of ARF and 30-day mortality
were not signiﬁcantly different between the two arms. Although
the 180-day mortality rate was signiﬁcantly lower in the nesiritide
group, nearly 30% of the patients were lost for this end point and
the possibility for attrition bias could not be excluded [10,11].
We sought to apply a decision analytic model to project the
effect of nesiritide on dialysis and mortality based on the renal
function preservation demonstrated in the NAPA trial. The base-
line renal function was also considered as an effect modiﬁer.
Methods
Literature Search
We performed a search of English literature (1997–January
2008) in PubMed to identify the currently best evidence that
would allow us to model the impact of postoperative renal func-
tion change on dialysis and mortality rates in patients undergoing
cardiac surgery. A search strategy with combination of both free
text key words and Medical Subject Headings (MeSH) terms
were used: (“Kidney Failure, Acute” [Mesh] OR “acute renal
failure” [Text Word]) and (“cardiac surgery” [Text Word] OR
“Thoracic Surgery” [MeSH] OR “Thoracic Surgical Procedures”
[MeSH] OR “Cardiovascular Surgical Procedures” [MeSH] OR
“Cardiac Surgical Procedures”[MeSH]). Clinical trials, observa-
tional studies and meta-analyses were included when the follow-
ing criteria were met: 1) studies included open-heart surgery
patients; 2) renal function was measured by GFR, SCr, or serum
creatinine clearance (CrCl); and 3) studies were conducted in
North America or in developed European countries to minimize
variation in the quality of surgery and postoperative care. The
following exclusion criteria were applied: 1) studies of heart
transplant, angioplasty, or heart-assist devices implant only; 2)
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studies of patients requiring presurgery dialysis; and 3) studies of
patients under 18 years of age.
We found 11 studies that fulﬁlled the selection criteria, all of
which had retrospective observational designs [4–7,12–18]. Evi-
dence from clinical trials or meta-analysis was unavailable.
Among the 11 studies, renal function measurements, clinical
outcomes, and follow-up times varied signiﬁcantly and their
ﬁndings could not be synthesized. Two studies were chosen as the
major references for the ﬁnal model development [7,12]. Both
studies investigated the impact of ARF on clinical outcomes in
large populations and evaluated a modifying effect of preopera-
tive renal function.
Decision Analytic Model
A decision analytical model (Fig. 1) was created to simulate the
NAPA trial. The model started from a decision node, where
hypothetical patients entered either the nesiritide or placebo arm.
Further branching out, two chance nodes were included in both
arms. The ﬁrst one represented the chance of requiring postop-
erative dialysis or not, and the second represented the chance of
hospital death or discharge from the hospital alive. The terminal
nodes at the end of each branch represented one of the following
four clinical states, respectively: dialysis and hospital death,
dialysis and discharge from hospital alive, no dialysis and hos-
pital death, or no dialysis and discharge form hospital alive.
Previous studies suggested that patients with preoperative RD
responded to nesiritide more positively than patients with normal
renal function (NRF) [10,19]. The model was therefore applied
to not only the total NAPA sample, but also to two subgroups
stratiﬁed by preoperative renal function status.
Our model had two inherent assumptions. First, nesiritide
was assumed to inﬂuence the incidence rates of dialysis and
hospital death through preserving renal function only. Second,
the predictive power of renal function on the selected clinical end
points as observed in the references was generalizable to the
NAPA trial patients.
Data Input
Renal function parameters. The modeled renal function param-
eters were preoperative renal function expressed as GFR (pre-
GFR) and postoperative renal function change expressed as GFR
change in percentage (%DGFR). Their distributions were based
on the published NAPA trial data, as presented in Table 1. In the
total NAPA sample, pre-GFR distributions were slightly different
between the two comparison groups, which were
82.0  30.3 ml/min/1.73 m2 in the nesiritide arm and
77.6  28.1 ml/min/1.73 m2 in the placebo arm. To avoid a
potential source of outcome variation unrelated to nesiritide, the
modeled pre-GFR was equalized to be 77.6  28.1 ml/min/
1.73 m2 for both arms. A triangle distribution was assigned to
this variable arbitrarily to avoid unreasonable values, with
minimum, likeliest, and maximum values deﬁned as lower, mean,
and upper 95% conﬁdence interval (CI) boundary values, respec-
tively. The 95% CI was calculated by using the standard Wald
method. For the change in GFR (%DGFR), we utilized NAPA
results reported as -11%  22% in the nesiritide arm and
-20%  24% in the placebo arm. A normal distribution was
assigned to %DGFR in each comparison arm [12].
The distributions of pre-GFR in the RD and NRF subgroups
were not released for the NAPA trial. For simplicity, we used
uniform distributions with a range of 22.5–60 ml/min/1.73 m2
for the RD subgroup and a range of 60–132.7 ml/min/1.73 m2
for the NRF subgroup. The change in GFR (%DGFR) in the RD
subgroup was reported as 1%  22% in the nesiritide arm and
-19%  23% in the placebo arm. Because %DGFR in the NRF
subgroup was not reported, we estimated it as -14.3%  27.5%
in the nesiritide arm and -20.3%  31.0% in the placebo arm by
using the equation set I (see Appendix), assuming normal distri-
butions of %DGFR in the total NAPA trial patients and both
subgroups.
Node probabilities. The probability of dialysis at the ﬁrst chance
node was obtained from Wijeysundera’s study, which found a
25% decline in CrCl to be the most relevant prognostic threshold
for postoperative dialysis [12]. According to this study, among
patients with preoperative RD, deﬁned as CrCl < 60 ml/min, the
probability of dialysis above or below this threshold was 0.2%
(1/462) and 15.8% (12/76), respectively. Among patients
without preoperative RD, the probability of dialysis above and
below this threshold was 0.0% (0/1335) and 5.5% (7/127),
respectively. To be consistent with the renal function measure-
Legend: Square signifies “decision nodes.” Circles signifies “chance node.” Triangle signifies “terminal 
node”. 
Figure 1 Decision Analytical Model.
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ment in the NAPA trial and because CrCl provides a good
approximation of GFR, the threshold of 25% decline in CrCl
was converted to 28.25% decline in GFR, by using the MDRD
formula. Accordingly, preoperative RD in our model was deﬁned
as GFR < 60 mg/min/1.73 m2. Given a hypothetical patient with
a pair of pre-GFR and %DGFR values, one of the four probabili-
ties would be taken as the point estimate for the dialysis chance
node. For example, with pre-GFR of 50 mg/min/1.73 m2 and
%DGFR of -50%, a patient had a chance of 15.8% to require
postoperative dialysis.
The probability of hospital death at the second chance node
was obtained from Thakar’s study, which quantiﬁed the indepen-
dent impact of %DGFR, pre-GFR on hospital mortality by using
a multivariate logistic regression model. According to a data
matrix provided in this study, we deduced the equation set II (see
Appendix), by which an adjusted odds ratio (OR) for hospital
mortality relative to a baseline risk can be calculated for a hypo-
thetical patient, given a pair of pre-GFR and %DGFR values [5].
The renal function at baseline was deﬁned as %DGFR of zero,
pre-GFR of 90 mg/min/1.73 m2 and dialysis free. When patients
were predicted to require dialysis after surgery, the hospital mor-
tality would be further increased by another OR of 4.2 (95% CI:
3.1–5.7), which was reported by Thakar et al. after controlling
for pre-GFR and %DGFR [5]. The baseline hospital mortality
was estimated at 1.3%, which was approximated from a 30-day
hospital mortality rate among 104,880 US heart surgery patients
with pre-GFR more than 90 ml/min/1.73 m2 [20]. This value was
applied to all hypothetical patients assuming no between-
individual variability. The probability at the hospital mortality
chance node therefore could be calculated for each hypothetical
patient given a pair of pre-GFR and %DGFR values, projected
dialysis status and the baseline mortality.
To incorporate uncertainties around the point estimates, prob-
ability distributions were assigned to the parameters that were
used to calculate node probabilities. As presented in Table 1, all
distributions were constructed with the 95% CIs. A uniform
distribution was assigned to the probability of dialysis among
patients with pre-GFR 60 mg/min/1.73 m2 and %DGFR
-28.5%. Lower and upper 95% CI boundary values were used
as the low and high values, respectively. Triangular distributions
were assigned to the other three dialysis probabilities, baseline
hospital mortality as well as the two hospital mortality ORs,
where minimal, likeliest, and maximal values were deﬁned as
lower, mean, and upper 95% CI boundary values, respectively.
Analysis
Base-Case Analysis
Monte Carlo simulations were performed to simulate the NAPA
trial with 1000 hypothetical patients in both nesiritide and
placebo arms. Monte Carlo simulation has two distinct features:
ﬁrst-order simulation and second-order simulation. The ﬁrst-
order simulation was used to account for individual variability.
For each hypothetical patient, it randomly picked a single path
through the model, passing down only one branch at each chance
node. The second-order simulation was used to account for
parameter uncertainty. When determining the node probabilities
for a hypothetical patient, it concurrently sampled a set of values
for model parameters within their prespeciﬁed distributions.
Three clinical end points were examined separately, which
were dialysis, hospital death, and a composite end point com-
bining both. All three end points were dichotomous, with a value
of 1 for the “event” terminal nodes and a value of 0 for the “no
event” terminal nodes. The direct model outputs mimicked
patient-level trial data, which were the incidence rates of the end
point events. Absolute risk reduction (ARR) and its 95% CI
between the nesiritide and placebo arms were calculated by using
the equation set III (see Appendix). The simulations were
repeated 100 times. Combined ARRs and their 95% CIs across
the 100 simulated trials were calculated additionally. All simu-
lations were implemented in TreeAge Pro 2008 (TreeAge Soft-
ware Inc., Williamstown, MA).
Best Case Analysis
Best case analyses were performed to test the robustness of the
base-case analyses. The analyses were restricted to the mean
%DGFR because it was the only model parameter that nesiritide
was proven to affect. The best case nesiritide analyses used the
95% CI boundary values of mean %DGFR favoring nesiritide
and unfavoring placebo. Oppositely, the best case placebo analy-
ses used the 95% CI boundary values of mean %DGFR unfavor-
ing nesiritide and favoring placebo.
Table 1 Decision analytic model inputs
Parameters Nesiritide Placebo
Total NAPA sample %DGFR Base-case Normal (-11.0%, 22.0%) Normal (-20.0%, 24.0%)
%DGFR Best case nesiritide Normal (-7.3%, 22.0%) Normal (-24.1%, 24.0%)
%DGFR Best case placebo Normal (-14.7%, 22.0%) Normal (-15.9%, 24.0%)
Pre-GFR (ml/min/1.73 m2) Triangle (22.5, 77.6, 132.7)
RD %DGFR Base-case Normal (1.0%, 22.0%) Normal (-19.0%, 23.0%)
%DGFR Best case nesiritide Normal (9.0%, 22.0%) Normal (-26.8%, 23.0%)
%DGFR Best case placebo Normal (-7.0%, 22.0%) Normal (-11.2%, 23.0%)
Pre-GFR Uniform (22.5–60.0)
Dialysis
Probability
GFR decline <28.25% Triangle (9.27%, 15.79%, 25.60%)
GFR decline >28.25% Triangle (0.04%, 0.22%, 1.22%)
NRF %DGFR Base-case Normal (-14.3%, 27.5%) Normal (-20.3%, 31.0%)
%DGFR Best case nesiritide Normal (-9.0%, 27.5%) Normal (-26.4%, 31.0%)
%DGFR Best case placebo Normal (-19.6%, 27.5%) Normal (-14.2%, 31.0%)
Pre-GFR (ml/min/1.73 m2) Uniform (60.0–132.7)
Dialysis
probability
GFR decline <28.25% Triangle (2.70%, 5.51%, 10.94%)
GFR decline >28.25% Uniform (0.00%, 0.20%)
Baseline all-cause hospital mortality Triangle (1.2%, 1.3%, 1.4%)
OR of a pair of pre-GFR and %DGFR Triangle Exp Ln OR OR Exp OR( ) − ×( ) ( ) + ×( )1 96 1 96. , , .Var Var
OR of dialysis Triangle (3.1, 4.2, 5.7)
NAPA, Nesiritide Administered Peri-Anesthesia in patients undergoing cardiac surgery trial; %DGFR, postoperative GFR change in percentage; GFR, glomerular ﬁltrate rate; NRF, normal renal
function at baseline; OR, odds ratio; Pre-GFR, preoperative GFR; RD, renal dysfunction at baseline.
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Results
Base-Case Analysis
The results of the base-case analyses are summarized in Table 2.
Because of the random nature of the Monte Carlo simulation, the
projected effects of nesiritide varied among the 100 trials. In the
total NAPA sample, nesiritide reduced dialysis, hospital death,
and composite rates in 48, 77, and 87 out of 100 trial repetitions,
respectively. None of the 100 simulated trials had signiﬁcantly
higher incidence rates in the nesiritide arm than placebo arm for
any of the three end points. The combined ARRs across 100
trials was 1.3% (95% CI: 1.1%, 1.4%) for dialysis, 3.3% (95%
CI: 3.1%, 3.6%) for hospital death, and 4.1% (95% CI: 3.9%,
4.4%) for the composite, respectively.
Subgroup analyses indicated a more pronounced effect of
nesiritide in the RD subgroup than the NRF subgroups. In the
RD subgroup, all of the 100 simulated trials signiﬁcantly favored
nesiritide for all three end points. The combined ARR increased
to 4.1% (95% CI: 4.0%, 4.3%) for dialysis, 7.1% (95% CI:
6.8%, 7.4%) for hospital death and 9.4% (9.1%, 9.7%) for
composite. The beneﬁcial effect of nesiritide diminished in the
NRF subgroup, yet no single trial signiﬁcantly favored placebo
for any of the three end points. The combined ARRs were 0.6%
(95% CI: 0.4%, 0.7%) for dialysis, 3.0% (95% CI: 2.8%, 3.3%)
for hospital death, and 3.4% (3.1%, 3.7%) for the composite.
Best Case Analysis
The best case analysis results are presented in Table 3. As
expected, the results became more favorable for nesiritide in the
best case nesiritide analyses. In the best case placebo analyses, the
effect of nesiritide remained positive in the total NAPA sample
and RD subgroup for all three end points, although less trials
signiﬁcantly favored nesiritide and the combined ARRs
decreased substantially. Conversely, the NRF subgroup results in
the best case placebo analysis reversed. There was no single trial
signiﬁcantly favoring nesiritide for any of the three end points.
Instead, 7, 3, and 2 trials signiﬁcantly favored placebo for dialy-
sis, hospital death, and composite, respectively. The combined
ARRs indicated a detrimental effect of nesiritide, which was
-0.4% (95% CI: -0.5%, -0.2%) for dialysis, -0.6% (95% CI:
-0.8%, -0.4%) for hospital death and -0.8% (95% CI: -1.1%,
-0.5%), respectively.
Discussion
The NAPA trial established a renal beneﬁt of nesiritide in
cardiac surgery patients and suggested possible beneﬁts on ARF
and mortality prevention. Compared with the placebo arm, the
nesiritide arm had lower ARF rate (7.1% vs. 12.3%, P = 0.219)
and lower 30-day mortality rate (2.8% vs. 5.9%, P = 0.160).
The 180-day mortality hazard ratio was 0.44 (95% CI 0.19–
Table 2 Monte Carlo simulation results for the base-case analyses
Outcome
Nesiritide
(%)
Placebo
(%)
ARR
(%)
Number of trials
signiﬁcantly favoring
nesiritide
Number of trials
signiﬁcantly favoring
placebo
Total NAPA sample Dialysis 2.0 3.3 1.3 (1.1, 1.4) 48 0
HM 7.2 10.5 3.3 (3.1, 3.6) 77 0
Composite 8.8 12.9 4.1 (3.9, 4.4) 87 0
RD Dialysis 2.0 6.1 4.1 (4.0, 4.3) 100 0
HM 8.3 15.4 7.1 (6.8, 7.4) 100 0
Composite 9.8 19.2 9.4 (9.1, 9.7) 100 0
NRF Dialysis 2.0 2.6 0.6 (0.4, 0.7) 11 0
HM 6.2 9.2 3.0 (2.8, 3.3) 79 0
Composite 7.9 11.3 3.4 (3.1, 3.7) 77 0
NAPA, Nesiritide Administered Peri-Anesthesia in patients undergoing cardiac surgery trial; ARR, absolute risk reduction; NRF, preoperative normal renal function; RD, preoperative renal
dysfunction.
Table 3 Monte Carlo simulation results for the best case analyses
Group Outcome
Nesiritide
(%)
Placebo
(%) ARR % (95% CI)
Number of trials
signiﬁcantly favoring
nesiritide
Number of trials
signiﬁcantly favoring
placebo
Best case Nesiritide Total Dialysis 1.6 3.9 2.3 (2.1, 2.4) 91 0
HM 6.2 12.1 5.8 (5.6, 6.1) 99 0
Composite 7.6 14.9 7.3 (7.0, 7.5) 100 0
RD Dialysis 1.3 8.2 7.0 (6.8, 7.2) 100 0
HM 6.5 19.1 12.6 (12.4, 12.9) 100 0
Composite 7.5 23.8 16.3 (16.0, 16.6) 100 0
NRF Dialysis 1.6 3.1 1.5 (1.3, 1.6) 65 0
HM 4.9 11.7 6.8 (6.5, 7.0) 100 0
Composite 6.3 13.9 7.6 (7.4, 7.9) 100 0
Best case Placebo Total Dialysis 2.4 2.7 0.3 (0.2, 0.4) 2 0
HM 8.2 9.0 0.3 (0.2, 0.4) 3 0
Composite 10.1 11.1 1.0 (0.7, 1.3) 6 0
RD Dialysis 3.3 4.3 1.0 (0.8, 1.2) 17 0
HM 10.4 11.9 1.5 (1.3, 1.8) 4 0
Composite 12.7 14.8 2.1 (1.8, 2.4) 16 0
NRF Dialysis 2.5 2.1 -0.4 (-0.5, -0.2) 0 7
HM 7.8 7.2 -0.6 (-0.8, -0.4) 0 3
Composite 9.8 9.0 -0.8 (-1.1, -0.5) 0 2
NAPA, Nesiritide Administered Peri-Anesthesia in patients undergoing cardiac surgery trial; ARR, absolute risk reduction; NRF, preoperative normal renal function; RD, preoperative renal
dysfunction.
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1.01) after exclusion of patients who lost to follow-up [10]. The
statistical inconclusiveness is not surprising because the NAPA
trial was powered to detect the effect of nesiritide on renal
function but not any level of morbidity or mortality [11]. We
were therefore intrigued to simulate the NAPA trial with a large
hypothetical sample. The effect of nesiritide was projected by
%DGFR with a full consideration of the modifying effect of
pre-GFR.
Consistent with the trends observed in the NAPA trial, the
base-case analyses suggest that nesiritide reduces the incidence
rates of dialysis and hospital death. Moreover, it is more beneﬁ-
cial for RD patients than NRF patients. According to the com-
bined ARRs, the number needed to be treated is 24.3 for dialysis,
14.1 for hospital death, and 10.6 for the composite in the RD
patients. They are 166.6, 33.3, and 29.4, respectively, in the NRF
patients. The best case analyses conﬁrmed the robustness of the
base-case results in the total NAPA sample and RD subgroup,
but not in the NRF subgroup. It reﬂects the fact that nesiritide
signiﬁcantly improved %DGFR in the total NAPA sample and
the RD subgroup, but not in the NRF subgroup. Although
%DGFR in the NRF subgroup was mathematically extrapolated,
we are conﬁdent that the clinical beneﬁt in the NRF subgroup,
even if signiﬁcant, would be much less than that in the RD
subgroup. Our results are consistent with an observational study
in which nesiritide was found associated with reduced 21-day
dialysis rates or hospital mortality in cardiac surgery patients
with preexisting RD (adjusted OR = 0.35; 95% CI 0.14–0.87)
but not in patients without pre-existing RD (OR = 1.55; 95%
CI = 0.48–5.07) [19]. The prevalence of preoperative RD is high
in cardiac surgery patients. A study analyzing the Society of
Thoracic Surgeon (STS) National Adult Cardiac Database
reported that during 2000–2003, approximately 125,000
patients receiving isolated coronary artery bypass had preopera-
tive GFR below 60 mg/min/1.73 m2. It accounts for nearly 26%
of all isolated coronary artery bypass patients included in this
dataset [20]. This subpopulation should be the primary focus in
the future nesiritide study.
Hospital mortality, regardless of timing, was the primary end
point in our model. It is the most often used end point in related
studies, probably because of its easiness to ascertain. The
primary mortality end point used by the STS 2008 cardiac
surgery risk models is operative mortality, deﬁned as death
during the same hospitalization as surgery, regardless of timing,
or within 30 days of surgery regardless of venue [21]. Neverthe-
less, it was admitted in the same report that approximately 90%
of the 30-day deaths occurred before hospital discharge and risk
estimations based on hospital mortality and the 30-day mortality
had little difference. One concern about hospital mortality may
rise from the possible inﬂuence of nesiritide use on discharge
decision. However, both patients and physicians were blinded in
the NAPA trial. The discharge decision in the reference study
populations were unlikely inﬂuenced by nesiritide use either
given the study time frames. Thus, our results were not biased by
the dependence between nesiritide use and discharge decision.
Dialysis was not only another projected end point, but also an
independent risk factor for hospital mortality. Implementation of
dialysis depends on a range of biological factors besides renal
function, which were not considered in this model. We do not
know if nesiritide inﬂuences the decision to implement dialysis in
clinical practice beyond its direct ability to lower SCr levels. All
analyses were repeated in another scenario where the dialysis
probability in the nesiritide arm was set to be equal to that in the
placebo arm. The results in the total NAPA sample and the two
subgroups were very close to the original scenario and the con-
clusions remained unchanged.
One challenge for the current study is how to disentangle the
risk attributed to renal failure from other risk factors. Another
challenge is how to select an appropriate renal function measure-
ment, as a variety of scales and thresholds were used in ARF
studies. The two references we chose provided solid evidence that
enabled us to address both issues [5,12]. We examined the basic
demographics of the reference study populations before we pro-
ceeded to model building. Similar to the NAPA trial patients,
reference study participants were mainly Caucasians, male in
gender, and with mean age between 61 and 65 years old. We
further conﬁrmed that the timing of maximum renal function
change measure was comparable with that in the NAPA trial,
which was during ICU stay, approximately 72 hours post surgery
(personal communication). Wijeysundera et al. systematically
evaluated different thresholds in different scales before the 25%
decline in CrCl was chosen to be the most valid threshold for
dialysis prediction [12]. Thakar et al. quantiﬁed the independent
impact of %DGFR, pre-GFR and dialysis on hospital mortality
after adjusting for a comprehensive range of risk factors in the
pre-, peri-, and postoperative phases [5]. Both studies measured
postoperative renal function in the form of percentage change
relative to the baseline, which accommodated variations related
to age, gender, and body mass index. More importantly, the
selected references are the only studies that investigated a modi-
fying effect of preoperative renal function. The major drawback
of both reference studies is their observational nature. The
observed associations between renal function and clinical out-
comes might be confounded by unmeasured factors. Neverthe-
less, these two references appear to represent the currently best
evidence in this ﬁeld.
We used two-dimensional Monte Carlo simulation to simu-
late the NAPA trial. It incorporated individual variability and
model parameter uncertainty concurrently. The simulation
results can be treated as patient-level clinical trial data [22]. One
dilemma of this technique is how to decide on an appropriate
number of simulations. Too few simulations would not predict
the outcome precisely and consistently, while too many simula-
tions would lead to unrealistically small variation. We solved this
issue by simulating a trial with a practical sample size of 1000
patients in each comparison arm and repeating the trial 100
times to improve the prediction accuracy. Based on our model, a
trial with 1000 patients in each comparison arm is very likely to
detect a signiﬁcant improvement in dialysis, hospital mortality,
and their composite in the RD patients, but much less likely in
the NRF patients. Thus, future trials should give priority to
patients with preexisting RD.
Our study has several limitations. First, themodel relied on the
validity of %DGFR as a surrogate outcome. A valid surrogate
outcome has to not only correlate, but also “fully capture the net
effect of treatment on the clinical outcome” [23]. We cannot
exclude the possibility that nesiritide affects the clinical end points
through pathways other than renal function. Nevertheless, a
broad range of clinical and biological outcomes were examined in
the NAPA trial and the only signiﬁcant ﬁndings were postopera-
tive renal function change and urine output. Nesiritide appears
not to inﬂuence the other investigated biological pathways in this
patient population. Urine output was not incorporated into our
model because the prevalent use of diuretics in cardiac surgery
patients makes it unreliable for prognostic purpose.
Second, characteristics of the NAPA trial patients might not
be same with the reference study populations’. The prediction
power of surrogate measures observed in the reference studies,
therefore, might not be applicable to the NAPA trial patients.
However, we did not detect any major discrepancies in the
reported basic demographics, and our literature review did not
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identify any effect modiﬁer other than preoperative renal func-
tion. It is unlikely that the mathematical associations between
renal functions and clinical outcomes were distorted by the other
concurrent conditions.
Third, we attempted to obtain individual renal function trial
data from the manufacturer, but they were not accessible. Hence
arbitrary distributions were assigned to individual variables and
model parameters. They might deviate from the true NAPA trial
data. Patient-speciﬁc covariates were also neglected in our model.
Finally, the effect of nesiritide on renal function change was
observed in a clinical trial setting. We do not know if the NAPA
trial ﬁndings, and consequently the model results, could be gen-
eralized to regular clinical settings. We also could not project the
long-term effect of nesiritide as we did not identify any high
quality references that allowed us to do so.
In conclusion, if the demonstrated preservation of postopera-
tive renal function can be extrapolated, nesiritide may decrease
the incidences of dialysis and hospital death in cardiac surgery
patient with preoperative RD, but to a much lesser extent, or
may not, in patients with normal preoperative renal function.
Current results warrant well-designed, large-scale clinical trials
to conﬁrm the effect of nesiritide on dialysis and mortality, espe-
cially in patients with preoperative RD.
Source of ﬁnancial support: There is no funding or any ﬁnancial support
received for this study.
Supporting information for this article can be found at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i5_He.asp
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